


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 015389-002611US
Client Reference No.: 018/063C

On February 25, 2003



TOWNSEND and TOWNSEND and CREW LLP

By: Maisie C. Livengood
Maisie C. Livengood

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Geron Corporation

Application No.: 09/432,503

Filed: November 2, 1999

For: HUMAN TELOMERASE
CATALYTIC SUBUNIT

Examiner: Peter P. Tung

Art Unit: 1652

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. With the exception of references AV, AW and AX, copies of which are enclosed, copies of the references can be found in U.S. Patent Application 08/912,951 filed August 14, 1997 (now U.S. Patent 6,475,789, issued November 5, 2002).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:mcl

COPY



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 12

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

U.S. PATENT DOCUMENTS

| Examiner | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|-----------------|-----------------------------------|--------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|
| | | Number | Kind Code ² (if known) | | | |
| | AA | 08/751,189 | | 11-15-96 | Harrington, et al. | |
| | AB | 60/038,750 | | 02-20-1997 | Counter, et al. | |
| | AC | 3,817,837 | | 06-18-1974 | Tanenholtz et al. | |
| | AD | 3,850,752 | | 11-26-1974 | Schuurs et al. | |
| | AE | 3,939,350 | | 02-17-1076 | Kronick et al. | |
| | AF | 3,996,345 | | 12-01-1976 | Ullman et al. | |
| | AG | 4,275,149 | | 06-23-1081 | Litman et al. | |
| | AH | 4,277,437 | | 07-07-1981 | Maggio | |
| | AI | 4,366,241 | | 12-28-1982 | Tom et al. | |
| | AJ | 4,683,195 | | 07-28-1987 | Mullis et al. | |
| | AK | 4,683,202 | | 07-28-1987 | Mullis | |
| | AL | 4,816,567 | | 03-28-1989 | Cabilly et al. | |
| | AM | 4,965,188 | | 10-23-1990 | Mullis et al. | |
| | AN | 5,489,508 | | 02-06-1996 | West et al. | |
| | AO | 5,583,016 | | 12-10-1996 | Villeponteau et al. | |
| | AP | 5,747,317 | | 05-05-1998 | Cao | |
| | AQ | 5,770,422 | | 06-23-1998 | Collins | |
| | AR | 6,093,809 | | 07-25-2000 | Cech, et al. | |
| | AS | 6,258,535 - B1 | | 07-10-2001 | Villeponteau et al. | |
| | AT | 6,261,556 - B1 | | 07-17-2001 | Weinrich et al. | |
| | AU | 6,261,836 - B1 | | 07-17-2001 | Cech et al. | |
| | AV | 6,093,809 | | 07-25-2000 | Cech et al. | |
| | AW | 6,166,178 | | 12/26-2000 | Cech et al. | |
| | AX | 6,475,789 B1 | | 11-05-2002 | Cech et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁹ |
|-----------------------|--------------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------|----------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | AY | JP | 09154575-A | | | 06-17-97 | | |
| | AZ | PCT | WO 84/03564 | | | 09-13-84 | | |
| | BA | PCT | WO 95/13382 | | | 05-18-95 | | |
| | BB | PCT | WO 96/01835 | | | 01-25-96 | | |
| | BC | PCT | WO 96/12811 | | | 05-02-96 | | |
| | BD | PCT | WO 96/19580 | | | 06-27-96 | | |
| | BE | PCT | WO 96/40868 | | | 12-19-96 | | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

DE 7096175 v1

COPY

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|--------------------------|--|
| Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> | | | Complete if Known | | |
| | | | Application Number | 09/432,503 | |
| | | | Filing Date | November 2, 1999 | |
| | | | First Named Inventor | Cech, Thomas R., et. al. | |
| | | | Art Unit | 1652 | |
| | | | Examiner Name | Peter P. Tung | |
| | | | Attorney Docket Number | 015389-002611US | |
| Sheet | 4 | of | 12 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | |
| | BF | PCT | WO 98/01542 | | | 01-15-98 | |
| | BG | PCT | WO 98/01543 | | | 01-15-98 | |
| | BH | PCT | WO 98/07838 | | | 03-05-98 | |
| | BI | PCT | WO 98/08938 | | | 02-26-98 | |
| | BJ | PCT | WO 98/21343 | | | 05-22-98 | |
| | BK | PCT | WO 98/37181 | | | 08-27-98 | |
| | BL | PCT | WO 98/45450 | | | 10-15-98 | |
| | BM | PCT | WO 98/59040 | | | 12/30/98 | |
| | BN | PCT | WO 99/01560 | | | 01/14/99 | |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **5** of **12****Complete if Known**

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | BO | 1994 Genome Issue of <i>Science</i> (265:1981f) | |
| | BP | Anderson and Young, "Quantitative Filter Hybridization" in <i>Nucleic Acid Hybridization</i> pp73-111 (1985) | |
| | BQ | Ausubel <i>et al.</i> ; (1989); Current Protocols in Molecular Biology; pp 5.1-5.11, 16.1-16.3 and 16.9-16.20; John Wiley & Sons, New York NY | |
| | BR | Autexier <i>et al.</i> , "Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA," (1996) <i>EMBO J.</i> , 15:5928 | |
| | BS | Auxexier and Greider, "Functional reconstitution of wild-type and mutant <i>Tetrahymena</i> telomerase," (1994) <i>Genes Develop.</i> , 8:563 | |
| | BT | Berger and Kimmel, <i>Guide to Molecular Cloning Techniques</i> ; (1987); Meth. Enzymol.; vol. 152; pp 305-389; Academic Press; San Diego CA | |
| | BU | Biessman <i>et al.</i> , "Addition of Telomere-Associated HeT DNA Sequences "Heals" Broken Chromosome Ends in <i>Drosophila</i> ," (1990) <i>Cell</i> , 61:663 | |
| | BV | Bitter <i>et al.</i> , "Expression and secretion vectors for yeast," Meth Enzymol., (1987) 153:516 | |
| | BW | Blackburn and Chiou, "Non-nucleosomal packaging of a tandemly repeated DNA sequence at termini of extrachromosomal DNA coding for rRNA in <i>Tetrahymena</i> ," (1981) <i>Proc. Natl. Acad. Sci.</i> , 78:2263 | |
| | BX | Blackburn and Gall, "A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in <i>Tetrahymena</i> ," (1978) <i>J. Mol. Biol.</i> , 120:33 | |
| | BY | Blackburn, "Telomerases," (1992) <i>Ann. Rev. Biochem.</i> , 61:113 | |
| | | Bodnar <i>et al.</i> , "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," (1998) <i>Science</i> , 279:349 | |
| | | Bradford, "A Rapid and Sensitive method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," (1976) <i>Anal. Biochem.</i> , 72:248 | |
| | | Braunstein <i>et al.</i> , "Transcriptional silencing in yeast is associated with reduced nucleosome acetylation," (1993) <i>Genes Develop.</i> , 7:592 | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

12

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | | Calvio <i>et al.</i> , "Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry," (1995) <i>RNA</i> , 1:724 | |
| | | Caruthers <i>et al.</i> , "New chemical methods for synthesizing polynucleotides," (1980) <i>Nucleic Acids Res. Symp. Ser.</i> , 215-223 | |
| | | Chan and Tye, "Organization of DNA sequences and replication origins at yeast telomeres," (1983) <i>Cell</i> , 33:563 | |
| | | Colbere-Garapin <i>et al.</i> , "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <i>J. Mol. Biol.</i> , 150:1 | |
| | | Cole <i>et al.</i> , "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss Inc., New York NY 77-96 (1985) | |
| | | Collins <i>et al.</i> , "Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme," (1995) <i>Cell</i> , 81:677 | |
| | | Conrad <i>et al.</i> , "RAP1 protein interacts with yeast telomeres in vivo: Overproduction alters telomere structure and decreases chromosome stability," (1990) <i>Cell</i> , 63:739 | |
| | | Coombs, <i>Dictionary of Biotechnology</i> , (1994); pp. 101-102, 283, 301 and 332; Stockton Press, New York NY | |
| | | Cote <i>et al.</i> , "Generation of human monoclonal antibodies reactive with cellular antigens," (1983) <i>Proc. Natl. Acad. Sci.</i> , 80:2026 | |
| | | Counter <i>et al.</i> , "The catalytic subunit of yeast telomerase," (1997) <i>Proc. Natl. Acad. Sci.</i> , 94:9202 | |
| | | Counter <i>et al.</i> , (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:2900 | |
| | | Creighton; <i>Proteins, Structures and Molecular Principles</i> ; (1983); pp. 1-60; WH Freeman and Co; New York, NY | |
| | | Dieffenbach and Dveksler, <i>PCR Primer, a Laboratory Manual</i> ; (1995) pp. 131-156, 453-462 and 507-580; Cold Spring Harbor Press, Plainview NY | |
| | | Duplax <i>et al.</i> , "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <i>Anal. Biochem.</i> , 212:229 | |

Examiner
Signature

Date

Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 12

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | | Fang <i>et al.</i> , "Oxytricha telomere-binding protein: separable DNA-binding and dimerization domains of the α -subunit," <i>Genes Develop.</i> 7:870 (1993) and Gray <i>et al.</i> , (1991) <i>Cell</i> 67:807 | |
| | | Feng <i>et al.</i> , "The RNA Component of Human Telomerase," (1995) <i>Science</i> , 269:1236 | |
| | | GenBank Accession No. AA281296; April 2, 1997 | |
| | | Genbank accession no. AA299878; April 18, 1997 | |
| | | Genbank accession no. AA311750; April 19, 1997 | |
| | | Gilley <i>et al.</i> , "Altering specific telomerase RNA template residues affects active site function," (1995) <i>Genes Develop.</i> , 9:2214 | |
| | | Gottschling and Cech, "Chromatin Structure of the Molecular Ends of Oxytricha Mononuclear DNA: Phased Nucleosomes and a Telomeric Complex," (1984) <i>Cell</i> , 38:501 | |
| | | Gottschling and Zakian, "Telomere proteins: specific recognition and protection of the natural termini of Oxytricha macronuclear DNA," (1986) <i>Cell</i> 47:195 | |
| | | Grant <i>et al.</i> , <i>Meth Enzymol.</i> , (1987) 153:516-544. | |
| | | Greenwood <i>et al.</i> , "Phylogenetic relationships within the class oligohymenophorea, phylum ciliophora, inferred from the complete small subunit rRNA gene sequences of <i>Colpidium campylum</i> , <i>Glaucoma chattoni</i> , and <i>Opisthionecta henneguyi</i> ," (1991) <i>J. Mol. Evol.</i> , 3:163 | |
| | | Greider and Blackburn, "A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis," (1989) <i>Nature</i> , 337:331 | |
| | | Greider and Blackburn, "Identification of a specific telomere terminal transferase activity in Tetrahymena extracts," (1985) <i>Cell</i> , 43:405 | |
| | | Greider, "Telomerase is processive," (1991) <i>Mol. Cell. Biol.</i> , 11:4572 | |
| | | Greider, "Telomere Length Regulation," (1996) <i>Ann. Rev. Biochem.</i> , 65:337 | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---------------------------------------------------------------------------------------------------|---|--------------------------|--------------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/432,503 |
| | | Filing Date | November 2, 1999 |
| | | First Named Inventor | Cech, Thomas R., et. al. |
| | | Art Unit | 1652 |
| | | Examiner Name | Peter P. Tung |
| | | Attorney Docket Number | 015389-002611US |
| Sheet | 8 | of | 12 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Hampton <i>et al.</i> ; <i>Serological Methods a Laboratory Manual</i> ; (1990); pp. 33-86, 179-286; APS Press, St Paul MN | |
| | | Harrington <i>et al.</i> , "A Mammalian Telomerase-Associated Protein," (1997) <i>Science</i> , 275:973 | |
| | | Harrington <i>et al.</i> , "Human telomerase contains evolutionarily conserved catalytic and structural subunits," (1997) <i>Genes Dev.</i> , 11:3109 | |
| | | Hartman and Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <i>Proc. Natl. Acad. Sci.</i> , 85:8047 | |
| | | Henderson and Blackburn, "An overhanging 3' terminus is a conserved feature of telomeres," (1989) <i>Mol. Cell. Biol.</i> , 9:345 | |
| | | Horn <i>et al.</i> , "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for gastric inhibitory polypeptide (GIP)," (1980) <i>Nucleic Acids Res. Symp. Ser.</i> , 225-232 | |
| | | Hudson <i>et al.</i> , "An STS-based map of the human genome," (1995) <i>Science</i> , 270:1945 | |
| | | Huse <i>et al.</i> , "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," (1989) <i>Science</i> , 246:1275 | |
| | | Johnson <i>et al.</i> , (1991) <i>Mol. Cell Biol.</i> 11:1 | |
| | | Kilian <i>et al.</i> , "Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types," (1997) <i>Hum. Mol. Genet.</i> , 6:2011 | |
| | | Kipling and Cooke, "Hypervariable ultra-long telomeres in mice," (1990) <i>Nature</i> 347:400 | |
| | | Klobutcher <i>et al.</i> , "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," (1981) <i>Proc. Natl. Acad. Sci.</i> , 78:3015 | |
| | | Koehler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <i>Nature</i> 256:495 | |
| | | Kosbor <i>et al.</i> , "The production of monoclonal antibodies from human lymphocytes," (1983) <i>Immunol. Today</i> 4:72 | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---------------------------------------------------------------------------------------------------|---|--------------------------|--------------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/432,503 |
| | | Filing Date | November 2, 1999 |
| | | First Named Inventor | Cech, Thomas R., et. al. |
| | | Art Unit | 1652 |
| | | Examiner Name | Peter P. Tung |
| | | Attorney Docket Number | 015389-002611US |
| Sheet | 9 | of | 12 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Lamond and Sproat; (1994) "Isolation and Characterization of Ribonucleoprotein Complexes;" In <i>RNA Processing: A Practical Approach</i> ; (Higgins, S.J. and Hawes, B.D. Eds.), Volume 1; pp103-140 | |
| | | Lamond <i>et al.</i> , "Probing the structure and function of U2 snRNP with antisense oligonucleotides made of 2'-OMe RNA," (1989) <i>Cell</i> , 58:383 | |
| | | Lendvay <i>et al.</i> , "Senescence mutants of <i>Saccharomyces cerevisiae</i> with a defect in telomere replication identify three additional EST genes," (1996) <i>Genetics</i> , 144 | |
| | | Lingner <i>et al.</i> , "Purification of telomerase from <i>Euplotes adeiculus</i> : requirement of a primer 3' overhang," (1996) <i>Proc. Natl. Acad. Sci.</i> , 93:10712 | |
| | | Lingner <i>et al.</i> , "Reverse transcriptase motifs in the catalytic subunit of telomerase," (1997) <i>Science</i> , 276:561 | |
| | | Lingner <i>et al.</i> , "Telomerase RNAs of different ciliates have a common secondary structure and a permuted template," (1994) <i>Genes Develop.</i> , 8:1984 | |
| | | Lingner <i>et al.</i> , "Telomerase and DNA End Replication: No Longer a Lagging Strand Problem?," (1995) <i>Science</i> 269:1533 | |
| | | Lowy <i>et al.</i> , "Isolation of transforming DNA: Cloning the hamster apt gene," (1980) <i>Cell</i> , 22:817 | |
| | | Lustig and Petes, Identification of yeast mutants with altered telomere structure," (1986) <i>Proc. Natl. Acad. Sci.</i> , 83:1398 | |
| | | Maddox <i>et al.</i> , "Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein," (1983) <i>J. Exp. Med.</i> , 158:1211 | |
| | | Makarov <i>et al.</i> , "Nucleosomal Organization of Telomere-Specific Chromatin in Rat," (1993) <i>Cell</i> , 73:775 | |
| | | McEachern and Blackburn, "runaway telomere elongation caused by telomerase RNA gene mutation," (1995) <i>Nature</i> , 376:403 | |
| | | Melby <i>et al.</i> , "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <i>J. Immunol. Meth.</i> , 159:235 | |
| | | Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," (1963) <i>J. Am. Chem. Soc.</i> , 85:2149 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **10** of **12****Complete if Known**

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | | Meyerson <i>et al.</i> , "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization," (1997) <i>Cell</i> , 90:785 | |
| | | Murray, <i>In McGraw Hill Yearbook of Science and Technology</i> , (1992) McGraw Hill, New York NY, pp 191-196 | |
| | | Nakamura <i>et al.</i> , "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," (1997) <i>Science</i> , 277:955 | |
| | | Nakayama <i>et al.</i> , "TLP1: A Gene Encoding a Protein Component of Mammalian Telomerase Is a Novel Member of WD Repeats Family," (1997) <i>Cell</i> , 88:875 | |
| | | Nielsen <i>et al.</i> , (1993) "Peptide nucleic acids (PNAs): Potential antisense and anti-gene agents," <i>Anticancer Drug Des.</i> , 8:53 | |
| | | Oka <i>et al.</i> , "Inverted terminal repeat sequence in the macronuclear DNA of <i>Stylonychia pustulata</i> ," (1980) <i>Gene</i> , 10:301 | |
| | | Olovnikov, "A theory of marginotomy: The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon," (1973) <i>J. Theor. Biol.</i> , 41:181 | |
| | | Orlandi <i>et al.</i> , "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <i>Proc. Natl. Acad. Sci.</i> , 86:3833 | |
| | | Prescott, "The DNA of ciliated protozoa," (1994) <i>Microbiol. Rev.</i> , 58:233 | |
| | | Price, (1993) <i>Blood Rev.</i> , 7:127 | |
| | | Rhodes <i>et al.</i> , "Transformation of maize by electroporation of embryos," (1995) <i>Meth. Mol. Biol.</i> , 55:121 | |
| | | Roberge <i>et al.</i> , "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) <i>Science</i> , 269:202 | |
| | | Romero and Blackburn, "A conserved secondary structure for telomerase RNA," (1991) <i>Cell</i> , 67:343 | |
| | | Sambrook <i>et al.</i> ; <i>Molecular Cloning, A Laboratory Manual</i> ; (1989); pp. 8.1-8.86 and 16.1-17.44; Cold Spring Harbor Press, Plainview NY | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

11

of

12

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | | Sandell <i>et al.</i> , "Transcription of yeast telomere alleviates telomere position effect without affecting chromosome stability," (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:12061 | |
| | | Sanger <i>et al.</i> , "DNA sequencing with chain-terminating inhibitors," (1977) <i>Proc. Natl. Acad. Sci.</i> , 74:5463 | |
| | | Scharf <i>et al.</i> , "Heat stress promoters and transcription factors," (1994) <i>Result Probl. Cell Differ.</i> 20:125 | |
| | | Shampay and Blackburn, "Generation of telomere-length heterogeneity in <i>Saccharomyces cerevisiae</i> ," (1988) <i>Proc. Natl. Acad. Sci.</i> , 85:534 | |
| | | Sheen and Levis, "Transposition of the LINE-like retrotransposon TART to <i>Drosophila</i> chromosome termini," (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:12510 | |
| | | Singer and Gottschling, "TLC1: Template RNA Component of <i>Saccharomyces cerevisiae</i> Telomerase," (1994) <i>Science</i> 266:404 | |
| | | Starling <i>et al.</i> , "Extensive telomere repeat arrays in mouse are hypervariable," (1990) <i>Nucleic Acids Res.</i> , 18:6881 | |
| | | Swanton <i>et al.</i> , "Arrangement of Coding and Non-coding Sequences in the DNA Molecules Coding for rRNAs in <i>Oxytricha</i> sp.," (1980) <i>Chromosoma</i> 77:203 | |
| | | Tommerup <i>et al.</i> , "Unusual chromatin in human telomeres," (1994) <i>Mol. Cell. Biol.</i> , 14:5777 | |
| | | Trask, "Fluorescence in situ hybridization: application in cytogenetics and gene mapping," (1991) <i>Trends Genet.</i> , 7:149 | |
| | | Verma <i>et al.</i> , "Human Chromosomes: A Manual of Basic Techniques," (1988); pp. 4-30, 152-190; Pergamon Press, New York NY | |
| | | Watson, "Origin of concatemeric T7 DNA," (1972) <i>Nature New Biol.</i> , 239:197 | |
| | | Weinrich <i>et al.</i> , "Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT," (1997) <i>Nat. Genet.</i> , 17(4):498-502 | |
| | | Wellinger <i>et al.</i> , "Origin activation and formation of single-strand TG ₁₋₃ tails occur sequentially in late S phase on a Yeast linear plasmid," (1993) <i>Mol. Cell. Biol.</i> , 13:4057 | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

COPY

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **12** of **12****Complete if Known**

| | |
|------------------------|--------------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech, Thomas R., et. al. |
| Art Unit | 1652 |
| Examiner Name | Peter P. Tung |
| Attorney Docket Number | 015389-002611US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| | | Wellinger <i>et al.</i> , "Saccharomyces Telomeres Acquire Single-Strand TG ₁₋₃ Tails Late in S Phase," (1993) <i>Cell</i> 72:51 | |
| | | Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28, 1995 | |
| | | Wigler <i>et al.</i> , "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) <i>Cell</i> , 11:223 | |
| | | Wigler <i>et al.</i> , "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <i>Proc. Natl. Acad. Sci.</i> , 77:3567 | |
| | | Winter and Milstein, "Man-made antibodies," (1991) <i>Nature</i> , 349:293 | |
| | | Wright <i>et al.</i> , "Saccharomyces telomeres assume a non-nucleosomal chromatin structure," (1992) <i>Genes Develop.</i> , 6:197 | |
| | | Yu <i>et al.</i> , "In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs," (1990) <i>Nature</i> , 344:126 | |
| | | Zahler and Prescott, "Telomere terminal transferase activity in the hypotrichous ciliate <i>Oxytricha nova</i> and a model for replication of the ends of linear DNA molecules," (1988) <i>Nucleic Acids Res.</i> , 16:6953 | |
| | | Zakian, Telomeres: Beginning to Understand the End," (1995) <i>Science</i> 270:1601 | |
| | | Zaug <i>et al.</i> , "Catalysis of RNA Cleavage by a Ribozyme Derived from the Group I Intron of Anabaena Pre-tRNA ^{Leu} ," (1996); <i>Nucleic Acids Research</i> ; 24:532-533 | |


Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7096175 v1

Express Mail Label No. EM 042 261 347 US
Date of Deposit: July 25, 2007



PATENT
Attorney Docket No.: 015389-002611US
Client Reference No.: 018/063C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas Cech et al.

Application No.: 09/432,503

Filed: November 2, 1999

For: REDUCING TISSUE DAMAGE
DUE TO IMPAIRED REPLICATION
USING A VECTOR FOR EXPRESSING
TELOMERASE REVERSE
TRANSCRIPTASE

Confirmation No.: 1130

Examiner: Angell, Jon E.

Art Unit: 1635

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In previously filed information disclosure statements, Applicants have identified certain related patents and pending non-provisional patent applications owned or co-owned by Geron Corporation with claims related to telomerase reverse transcriptase (e.g., claiming telomerase reverse transcriptase protein sequences, and/or telomerase reverse transcriptase nucleic acid protein encoding sequences, and/or telomerase reverse transcriptase promoter sequences, and/or cells or compositions comprising such protein or nucleic acid sequences, and/or the use of such proteins, nucleic acids, cell or compositions). For the convenience of the Office, in this supplemental IDS Applicants have provided an updated list (below) of related patents and applications including additional patents and applications. The tables below also show the status of pending applications and indicates where there have been one or more adverse decisions by the Office related to pending claims. Copies of the issued or most recently pending claims are

included for the convenience of the examiner and are listed in the accompanying PTO/SB08B by reference number as shown in the table.

In connection with the claims pending in the instant application (related to a method of increasing the proliferative capacity of a mammalian cell expressing telomerase RNA component by introducing into the cell *in vitro* a recombinant polynucleotide that encodes a protein with telomerase catalytic activity) Applicants draw the attention of the Office to U.S. Pat. Nos. 7,195,911; 6,475,789; 6,261,836; 6,337,200; and 6,921,664; and allowed application No. 09/721,506. These patents and application include claims directed to cells comprising a polynucleotide encoding a protein with telomerase catalytic activity.

It is understood that the Office has access to the full patent specifications, file histories, and other information via PAIR. However, should the Office require copies of any documents the Office is urged to contact the undersigned. Moreover, although Applicants have provided this information in an attempt to assist the Office, it is Applicants' understanding that the Examiner will conduct his own analysis.

Applicants have provided this information in an attempt to assist the Office; however it is Applicants' understanding that the Examiner will conduct his/her analysis of the materials submitted herewith.

Summary

| Patent No. | Title | Claims |
|--------------------|----------------------------------------------------------------------------------------------------|--------|
| Pat. No. 6,093,809 | Telomerase | AU |
| Pat. No. 6,166,178 | Telomerase Catalytic Subunit | AV |
| Pat. No. 6,261,836 | Telomerase | AW |
| Pat. No. 6,309,867 | Telomerase | AX |
| Pat. No. 6,444,650 | Antisense Compositions For Detecting And Inhibiting Telomerase Reverse Transcriptase | AY |
| Pat. No. 6,475,789 | Telomerized Mammalian Cells Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods | AZ |
| Pat. No. 6,617,110 | Cells Immortalized with Telomerase Reverse Transcriptase for Use in Drug Screening | BA |
| Pat. No. 6,627,619 | Antisense Compositions for Detecting and Inhibiting Telomerase Reverse Transcriptase | BB |

| Patent No. | Title | Claims |
|--------------------|------------------------------------------------------------------------------------------------|--------|
| Pat. No. 6,808,880 | Method for Detecting Polynucleotided Encoding Telomerase | BC |
| Pat. No. 6,921,664 | Telomerase | BD |
| Pat. No. 6,927,285 | Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants | BE |
| Pat. No. 7,005,262 | Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase | BF |
| Pat. No. 7,056,513 | Telomerase | BG |
| Pat. No. 7,195,911 | Mammalian Cells that have Increased Proliferative Capacity | BH |
| Pat. No. 7,091,021 | Inactive Variants of the Human Telomerase Catalytic Subunit | BI |
| Pat. No. 6,337,200 | Human Telomerase Catalytic Subunit Variants | BJ |
| Pat. No. 6,610,839 | Promoter For Telomerase Reverse Transcriptase | BK |
| Pat. No. 6,767,719 | Mouse Telomerase Reverse Transcriptase | BL |
| Pat. No. 6,777,203 | Telomerase Promoter Driving Expression of Therapeutic Gene Sequences | BM |
| Pat. No. 6,440,735 | Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer | BN |

| App. No. | Title | Status | Pending Claims |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| 09/432,503 (This application) | Reducing Tissue Damage Due to Impaired Replication Using a Vector for Expressing Telomerase Reverse Transcriptase | In most recent O.A., previous claims were rejected under 35 USC § 112 ¶ 1 (enablement). | BO |
| 09/721,477 | Immunogenic Nucleic Acid Sequences of Human Telomerase Reverse Transcriptase | In most recent O.A., previous claims were rejected under 35 USC § 112 ¶ 1 (new matter, written description and enablement requirements); §§ 102 and 103 (citing GeneBank Accession No. AA281296). | BP |
| 09/721,506 | Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs | Allowed | BQ |
| 10/877,124 | Vector Encoding Inactivated Telomerase for Treating Cancer | No examination on the merits | BR |
| 10/877,146 | Vaccine Containing the Catalytic Subunit of Telomerase for Treating Cancer | No examination on the merits - Now Abandoned | BS |

| App. No. | Title | Status | Pending Claims |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| 10/877,022 | Treating Cancer Using a Telomerase Vaccine (Immunodetection of hTERT proteins) | In most recent O.A., claims are rejected under 35 USC § 112 ¶ 1 (written description and enablement requirements); and 35 USC § 112 ¶ 2 | BT |
| 11/207,078 | Sequence of Telomerase Reverse Transcriptase, and Products Derived Therefrom for Conducting Clinical Assays, Immortalizing Cells, Screening Drugs, Treating Cancer, and for Other Commercial Purposes | No examination on the merits | BU |
| 10/044,692 | Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase | In most recent O.A., previous claims were rejected under 35 USC § 112 ¶ 1 (written description and enablement requirements); and for obviousness-type double patenting over Pat. Nos. 6,093,809 and 6,261,836. | BV |
| 08/974,584 | Functional Homologs of Human Telomerase Reverse Transcriptase Containing the Telomerase T Motif | Obviousness-type double patenting rejections citing Pat. Nos. 6,261,836; 6,927,285; 6,921,664; 6,337,200; 6,475,789; 7,195,911 and Application Nos. 09/721,477; 10/877,124; 09/721,506; 11/207,078 and 10/044,692. | BW |
| 10/053,758 | Antibody to Telomerase Reverse Transcriptase | Allowed | BX |
| 10/637,443 | Identifying and Testing Antisense Oligonucleotides that Inhibit Telomerase Reverse Transcriptase | Rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; and 112 ¶ 2 | BY |
| 10/862,698 | Protein and Peptide Fragments from Mouse Telomerase Reverse Transcriptase | Abandoned in favor of continuation. Prior claims were rejected under 35 USC § 112 ¶ 1 written description and enablement requirements; § 102; and § 103 | BZ |
| 09/615,039 | Oncolytic Virus that Replicates in Cells Expressing Telomerase Reverse Transcriptase | Abandoned Rejection under 35 USC § 112 ¶ 1 written description and enablement requirements; § 112 ¶ 2; § 102, § 103; and obviousness-type double patenting | CA |
| 11/411,604 | Telomerase Promoter Sequences for Screening Telomerase Modulators (Con of 09/615,039) | No substantive examination on the merits | CB |
| 10/208,243 | Method for Identifying and Killing Cancer Cells (Con of Pat. No. 6,440,735) | Non-final rejection under 35 USC § 112 ¶ 1 written description and 35 USC § 112 ¶ 1 | CC |
| 11/413,838 | Cellular Telomerase Vaccine and Its Use for Treating Cancer (Div of 10/208,243) | No examination on the merits | CD |

| App. No. | Title | Status | Pending Claims |
|------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------|
| 10/674,836 | Cancer Therapy Using the Telomerase Promoter | Rejection under 35 USC § 112 ¶ 1 written description and enablement; double patenting over 6,777,203 35 USC § 112 ¶ 1 | CE |


References cited on the attached PTO/SB/08A and PTO/SB/08B forms

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Randolph Ted Apple
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RTA:crf



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/432,503 |
| Filing Date | November 2, 1999 |
| First Named Inventor | Cech |
| Art Unit | 1635 |
| Examiner Name | Angell, J. E. |
| Attorney Docket Number | 015389-002611US |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 5 |
|-------|---|----|---|

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|------------------------------------------|--------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|
| | | Number Kind Code ² (if known) | | | |
| | AA | US-7,195,911 B2 | 03-27-2007 | Cech et al. | |
| | AB | US-7,091,021 B2 | 08-15-2006 | Morin | |
| | AC | US-7,056,513 B2 | 06-06-2006 | Cech et al. | |
| | AD | US-7,005,262 B2 | 02-28-2006 | Cech et al. | |
| | AE | US-6,927,285 B2 | 08-09-2005 | Cech et al. | |
| | AF | US-6,921,664 B2 | 07-26-2005 | Cech et al. | |
| | AG | US-6,808,880 B2 | 10-26-2004 | Cech et al. | |
| | AH | US-6,777,203 B1 | 08-17-2004 | Morin et al. | |
| | AI | US-6,767,719 B1 | 07-27-2004 | Morin et al. | |
| | AJ | US-6,627,619 B1 | 09-30-2003 | Cech et al. | |
| | AK | US-6,617,110 B1 | 09-09-2003 | Cech et al. | |
| | AL | US-6,610,839 B1 | 08-26-2003 | Morin et al. | |
| | AM | US-6,475,789 B1 | 11-05-2002 | Cech et al. | |
| | AN | US-6,444,650 B1 | 09-03-2002 | Cech et al. | |
| | AO | US-6,440,735 B1 | 08-27-2002 | Gaeta | |
| | AP | US-6,337,200 B1 | 01-08-2002 | Morin | |
| | AQ | US-6,309,867 | 10-30-2001 | Cech et al. | |
| | AR | US-6,261,836 | 07-17-2001 | Cech et al. | |
| | AS | US-6,166,178 | 12-26-2000 | Cech et al. | |
| | AT | US-6,093,809 | 07-25-2000 | Cech et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/432,503 |
| | | | | Filing Date | November 2, 1999 |
| | | | | First Named Inventor | Cech |
| | | | | Art Unit | 1635 |
| | | | | Examiner Name | Angell, J. E. |
| Sheet | 2 | of | 5 | Attorney Docket Number | 015389-002611US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | AU | Claims for U.S. Patent No. 6,093,809. | <input type="checkbox"/> |
| | AV | Claims for U.S. Patent No. 6,166,178. | <input type="checkbox"/> |
| | AW | Claims for U.S. Patent No. 6,261,836. | <input type="checkbox"/> |
| | AX | Claims for U.S. Patent No. 6,309,867. | <input type="checkbox"/> |
| | AY | Claims for U.S. Patent No. 6,444,650. | <input type="checkbox"/> |
| | AZ | Claims for U.S. Patent No. 6,475,789. | <input type="checkbox"/> |
| | BA | Claims for U.S. Patent No. 6,617,110. | <input type="checkbox"/> |
| | BB | Claims for U.S. Patent No. 6,627,619. | <input type="checkbox"/> |
| | BC | Claims for U.S. Patent No. 6,808,880. | <input type="checkbox"/> |
| | BD | Claims for U.S. Patent No. 6,921,664. | <input type="checkbox"/> |
| | BE | Claims for U.S. Patent No. 6,927,285. | <input type="checkbox"/> |
| Examiner Signature | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/432,503 |
| | | | | Filing Date | November 2, 1999 |
| | | | | First Named Inventor | Cech |
| | | | | Art Unit | 1635 |
| | | | | Examiner Name | Angell, J. E. |
| Sheet | 3 | of | 5 | Attorney Docket Number | 015389-002611US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | BF | Claims for U.S. Patent No. 7,005,262. | <input type="checkbox"/> |
| | BG | Claims for U.S. Patent No. 7,056,513. | <input type="checkbox"/> |
| | BH | Claims for U.S. Patent No. 7,195,911. | <input type="checkbox"/> |
| | BI | Claims for U.S. Patent No. 7,091,021. | <input type="checkbox"/> |
| | BJ | Claims for U.S. Patent No. 6,337,200. | <input type="checkbox"/> |
| | BK | Claims for U.S. Patent No. 6,610,839. | <input type="checkbox"/> |
| | BL | Claims for U.S. Patent No. 6,767,719. | <input type="checkbox"/> |
| | BM | Claims for U.S. Patent No. 6,777,203. | <input type="checkbox"/> |
| | BN | Claims for U.S. Patent No. 6,440,735. | <input type="checkbox"/> |
| | BO | Pending claims for US patent application 09/432,503. | <input type="checkbox"/> |
| | BP | Pending claims for US patent application 09/721,477. | <input type="checkbox"/> |
| Examiner Signature | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/432,503 |
| | | | | Filing Date | November 2, 1999 |
| | | | | First Named Inventor | Cech |
| | | | | Art Unit | 1635 |
| | | | | Examiner Name | Angell, J. E. |
| Sheet | 4 | of | 5 | Attorney Docket Number | 015389-002611US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | BQ | Pending claims for US patent application 09/721,506. | <input type="checkbox"/> |
| | BR | Pending claims for US patent application 10/877,124. | <input type="checkbox"/> |
| | BS | Pending claims for US patent application 10/877,146. | <input type="checkbox"/> |
| | BT | Pending claims for US patent application 10/877,022. | <input type="checkbox"/> |
| | BU | Pending claims for US patent application 11/207,078. | <input type="checkbox"/> |
| | BV | Pending claims for US patent application 10/044,692. | <input type="checkbox"/> |
| | BW | Pending claims for US patent application 08/974,584. | <input type="checkbox"/> |
| | BX | Pending claims for US patent application 10/053,758. | <input type="checkbox"/> |
| | BY | Pending claims for US patent application 10/637,443. | <input type="checkbox"/> |
| | BZ | Claims previously pending in US patent application 10/862,698 (abandoned).. | <input type="checkbox"/> |
| | CA | Claims previously pending in US patent application 09/615,039 (abandoned). | <input type="checkbox"/> |
| Examiner Signature | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/432,503 |
| | | | | Filing Date | November 2, 1999 |
| | | | | First Named Inventor | Cech |
| | | | | Art Unit | 1635 |
| | | | | Examiner Name | Angell, J. E. |
| Sheet | 5 | of | 5 | Attorney Docket Number | 015389-002611US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CB | Pending claims for US patent application 11/411,604. | <input type="checkbox"/> |
| | CC | Pending claims for US patent application 10/208,243. | <input type="checkbox"/> |
| | CD | Pending claims for US patent application 11/413,838. | <input type="checkbox"/> |
| | CE | Pending claims for US patent application 10/674,836. | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.